

## **In silico drug design of novel isatin derivatives as PI3K inhibitors**

**Gopinath palanisamy**

RVS College of Pharmaceutical Sciences, India

**T**riple negative breast Cancer (TNBC) , refers to the fact that the cancer cells don't have estrogen or progesterone receptors (ER or PR) and also don't make any or too much of protein called HER2.( The cells test "negative" on all 3 tests ) .TNBC is considered as one of the most aggressive types of Cancer . In TNBC targeting PI3K( phosphoinositide 3 kinase),is a part of large family of lipid kinase that phosphorylate the 3 – hydroxyl group of phosphoinositides , involved in the

regulation of diverse cellular process including cell proliferation ,survival and migration. Metastatic TNBC had a bad prognosis. As a result more targeted techniques are desperately required , we will discuss current clinical advancement in targeted strategies for TNBC such as to develop new PI3K pathway specific inhibitors produce the therapeutic break through that is desperately needed.

**Received dates:** October 10, 2022; **Accepted dates:** October 12, 2022; **Published dates:** October 31, 2022